Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Neurotherapeutics ; 12(3): 657-66, 2015 Jul.
Article de Anglais | MEDLINE | ID: mdl-25916397

RÉSUMÉ

Autism is a developmental disorder characterized by impairments in social and communication abilities, as well as by restricted and repetitive behaviors. Incidence of autism is higher than earlier estimates, and treatments have limited efficacy and are costly. Limited clinical and experimental evidence suggest that patients with autism may benefit from electroconvulsive therapy (ECT). We examined the therapeutic potential of ECT in BTBR T+ tf/j mice, which represent a validated model of autism. A series of 13 electroconvulsive shocks (ECS) delivered twice a day over 7 days reversed core autism-like behavioral abnormalities-impaired sociability, social novelty, and repetitive behavior-when the animals were tested 24 h after the last ECS. The effect lasted up to 2 weeks after ECT. Neither single ECS nor a series of 6 ECS modified animals' behavior. Chronic infusion into the lateral brain ventricle of a preferential oxytocin receptor blocker (2S)-2-Amino-N-[(1S,2S,4R)-7,7-dimethyl-1-[[[4-(2-methylphenyl)-1-piperazinyl]sulfonyl]methyl]bicyclo[2.2.1]hept-2-yl]-4-(methylsulfonyl)butanamide hydrochloride abolished ECT-induced improvement of sociability and mitigated improvement of social novelty but did not affect ECT-induced reversal of repetitive behavior. These proof-of-principle experiments suggest that ECT may, indeed, be useful in the treatment of autism, and that its therapeutic effects may be mediated, in part, by central oxytocin signaling.


Sujet(s)
Trouble autistique/thérapie , Comportement animal/effets des médicaments et des substances chimiques , Électroconvulsivothérapie , Comportement social , Animaux , Trouble autistique/psychologie , Camphanes/administration et posologie , Camphanes/pharmacologie , Modèles animaux de maladie humaine , Perfusions intraventriculaires , Souris , Souris de lignée C57BL , Lignées consanguines de souris , Pipérazines/administration et posologie , Pipérazines/pharmacologie , Récepteurs à l'ocytocine/antagonistes et inhibiteurs , Récepteurs à l'ocytocine/physiologie , Résultat thérapeutique
2.
PLoS One ; 9(3): e93283, 2014.
Article de Anglais | MEDLINE | ID: mdl-24681760

RÉSUMÉ

Anemia of cancer (AC) may contribute to cancer-related fatigue and impair quality of life. Improved understanding of the pathogenesis of AC could facilitate better treatment, but animal models to study AC are lacking. We characterized four syngeneic C57BL/6 mouse cancers that cause AC. Mice with two different rapidly-growing metastatic lung cancers developed the characteristic findings of anemia of inflammation (AI), with dramatically different degrees of anemia. Mice with rapidly-growing metastatic melanoma also developed a severe anemia by 14 days, with hematologic and inflammatory parameters similar to AI. Mice with a slow-growing peritoneal ovarian cancer developed an iron-deficiency anemia, likely secondary to chronically impaired nutrition and bleeding into the peritoneal cavity. Of the four models, hepcidin mRNA levels were increased only in the milder lung cancer model. Unlike in our model of systemic inflammation induced by heat-killed Brucella abortus, ablation of hepcidin in the ovarian cancer and the milder lung cancer mouse models did not affect the severity of anemia. Hepcidin-independent mechanisms play an important role in these murine models of AC.


Sujet(s)
Anémie par carence en fer/étiologie , Anémie par carence en fer/anatomopathologie , Tumeurs/complications , Tumeurs/anatomopathologie , Anémie par carence en fer/génétique , Animaux , Brucella abortus/métabolisme , Modèles animaux de maladie humaine , Femelle , Hepcidines/génétique , Inflammation/génétique , Inflammation/anatomopathologie , Mâle , Souris , Souris de lignée C57BL , Tumeurs/génétique , Qualité de vie , ARN messager/génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE